161 related articles for article (PubMed ID: 38477852)
1. Spatiotemporal-Controlled NIR-II Immune Agonist Sensitizes Cancer Immunotherapy.
Guo S; Tang D; Zhang M; Yang H; Zhang T; Hu B; Xu C; Weng Y; Shang K; Huang Y
Adv Mater; 2024 Jun; 36(25):e2400228. PubMed ID: 38477852
[TBL] [Abstract][Full Text] [Related]
2. Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators.
Sun H; Yu T; Li X; Lei Y; Li J; Wang X; Peng P; Ni D; Wang X; Luo Y
J Nanobiotechnology; 2021 Dec; 19(1):433. PubMed ID: 34930269
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional nanoparticles precisely reprogram the tumor microenvironment and potentiate antitumor immunotherapy after near-infrared-II light-mediated photothermal therapy.
Ge Y; Zhang J; Jin K; Ye Z; Wang W; Zhou Z; Ye J
Acta Biomater; 2023 Sep; 167():551-563. PubMed ID: 37302731
[TBL] [Abstract][Full Text] [Related]
4. Lipid-Polymer Hybrid Nanoparticles with Both PD-L1 Knockdown and Mild Photothermal Effect for Tumor Photothermal Immunotherapy.
Chuan D; Fan R; Chen B; Ren Y; Mu M; Chen H; Zou B; Dong H; Tong A; Guo G
ACS Appl Mater Interfaces; 2023 Sep; 15(36):42209-42226. PubMed ID: 37605506
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
7. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.
Tang Y; Chang Q; Chen G; Zhao X; Huang G; Wang T; Jia C; Lu L; Jin T; Yang S; Cao L; Zhang X
Biomater Adv; 2023 Jul; 150():213425. PubMed ID: 37084635
[TBL] [Abstract][Full Text] [Related]
8. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
9. Precision USPIO-PEG-SLe
Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G
Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177
[TBL] [Abstract][Full Text] [Related]
10. IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation.
Wang Y; Wang H; Song Y; Lv M; Mao Y; Song H; Wang Y; Nie G; Liu X; Cui J; Zou X
J Nanobiotechnology; 2022 Mar; 20(1):96. PubMed ID: 35236356
[TBL] [Abstract][Full Text] [Related]
11. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
12. Activating CD8
Wang B; Zhou J; Li R; Tang D; Cao Z; Xu C; Xiao H
Adv Mater; 2024 May; 36(21):e2311640. PubMed ID: 38341667
[TBL] [Abstract][Full Text] [Related]
13. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
Tang H; Xu X; Chen Y; Xin H; Wan T; Li B; Pan H; Li D; Ping Y
Adv Mater; 2021 Mar; 33(12):e2006003. PubMed ID: 33538047
[TBL] [Abstract][Full Text] [Related]
15. GSH/pH dual response drug delivery system for photothermal enhanced gene-immunotherapy.
Ma T; Li W; Ye J; Huang C; Li Y; Qiu H; Yin S
Nanoscale; 2023 Nov; 15(42):16947-16958. PubMed ID: 37779508
[TBL] [Abstract][Full Text] [Related]
16. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
17. Self-delivery of metal-coordinated NIR-II nanoadjuvants for multimodal imaging-guided photothermal-chemodynamic amplified immunotherapy.
Dai Y; Li X; Xue Y; Chen K; Jiao G; Zhu L; Li M; Fan Q; Dai Y; Zhao Q; Shen Q
Acta Biomater; 2023 Aug; 166():496-511. PubMed ID: 37230439
[TBL] [Abstract][Full Text] [Related]
18. Second Near-Infrared Photothermal Semiconducting Polymer Nanoadjuvant for Enhanced Cancer Immunotherapy.
Li J; Yu X; Jiang Y; He S; Zhang Y; Luo Y; Pu K
Adv Mater; 2021 Jan; 33(4):e2003458. PubMed ID: 33325584
[TBL] [Abstract][Full Text] [Related]
19. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8
Huang MY; Chen YC; Lyu WY; He XY; Ye ZH; Huang CY; He XL; Chen X; Chen X; Zhang B; Kai G; Zhang X; Li T; Huang M; Lu JJ
Pharmacol Res; 2023 Dec; 198():106988. PubMed ID: 37984507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
